Rapport Therapeutics, INC Form 4 insider transactions

Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, was granted stock options for 84,904 shares of common stock on June 6, 2024.

Third Rock Ventures converted its holdings of Series A and Series B Preferred Stock into Common Stock of Rapport Therapeutics upon the closing of the company's initial public offering.

Rapport Therapeutics CEO Abraham Ceesay was granted stock options to purchase 530,647 shares of common stock on June 6, 2024.

Director James Healy reports changes in beneficial ownership of Rapport Therapeutics common stock following the company's initial public offering.

Troy A. Ignelzi, CFO of Rapport Therapeutics, acquired stock options for 81,366 shares on June 6, 2024, according to a Form 4 filing.